Scholars Central

Conference abstractPublished 2018

Multi-bio-marker spatial interactions require high dimensional tissue analysis

Authors: Fabian Schneider, Florian Leiss, Ralf Huss, Andreas Spitzmuller, Arno Schaepe, Moritz Widmaier

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The interaction of tumor cells and their associated tumor microenvironment (TME) is a highly complex and usually heterogenous system, individual for each patient. Simple scores as used for scoring programmed death-ligand 1 (PD-L1) expression related to Immuno-Oncology (IO) treatment decisions are of limited value, as they capture an incomplete picture of the patients’ tumor-TME interactions. Developing a multiplexed seven marker IHC, a biomarker panel (IOPanel), we were able to unlock the heterogeneity of the TME in mesothelioma and NSCLC with our unique TissuePhenomics® approach. In first step, the results categorized the samples into hot or cold tumors, based on the presence of tumor infiltrating lymphocytes. In a second step, the combined analysis of all seven biomarkers allowed us to sub-classify patient tumor samples into six IO-related categories. These six categories are based on the currently available literature and published clinical outcome data and can be associated with patient response to IO treatments. Furthermore, the categorization allows the recommendation of patient-specific treatment decisions. Machine learning revealed spatial TME heterogeneity in those tumors. In a data driven clustering approach, we could decipher 12 distinct IO-patterns. Some of these patterns showed a clear overlap with the hypothesis-generated six IO-categories. Others revealed currently nonconsidered tumor immune-phenotypes, providing a more detailed description of the tissue architecture, than the initial six IO-categories. In summary, our standardized IO-Panel showed that patients with hot and cold tumors can be classified into six distinct IO-categories and tumor tissue into six distinct local IOphenotypes. Future studies with increased patient sample cohorts and available outcome data are needed to prove their clinical relevance.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Archives in Cancer Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalArchives in Cancer Research
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Fabian Schneider”
  • BylineArticles whose byline prints “Florian Leiss”
  • BylineArticles whose byline prints “Ralf Huss”
  • BylineArticles whose byline prints “Andreas Spitzmuller”
  • BylineArticles whose byline prints “Arno Schaepe”
  • BylineArticles whose byline prints “Moritz Widmaier”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels